Dry Eye Disease Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Dry Eye Disease Pipeline Insight 2024" report provides comprehensive insights about 45+ Dry Eye Disease companies and 50+ Dry Eye Disease pipeline drugs in Dry Eye Disease pipeline landscape. It covers the Dry Eye Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dry Eye Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Dry Eye Disease Pipeline Report
• Over 45+ Dry Eye Disease companies are evaluating 50+ Dry Eye Disease pipeline therapies in various stages of development, and their anticipated acceptance in the Dry Eye Disease market would significantly increase market revenue.
• Several prominent Dry Eye Disease companies are actively involved in the market, including Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, Seikagaku Corporation, Aramis Biosciences, Dreamhawk Vision Biotech Inc., Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa, and others.
• Promising Dry Eye Disease Pipeline Therapies in the various stages of development include OK-101, SHJ002/Vehicle, TL-925, SY-201 Ophthalmic Solution 2.0%, K-161, Tivanisiran sodium ophthalmic solution, Oxervate, HU007, Restasis, Moisview Eye drop, Masked Ikervis, and others.
• April 2024: AJU Pharm Co. Ltd, announced a study of Phase 2 clinical trials for AJU-S56 5%. This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56) compared to control drug(vehicle) in Patients with Dry Eye Disease.
• March 2024: Stuart Therapeutics Inc. announced a study of Phase 2 clinical trials for ST-100 Ophthalmic Solution. The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.

Request a sample and discover the recent advances in Dry Eye Disease Treatment Drugs @ Dry Eye Disease Pipeline Outlook Report- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Dry Eye Disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Eye Disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Eye Disease clinical trial landscape.

Dry Eye Disease Overview
Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular suface inflammation and damage, and neuorsensory abnormalities.

Find out more about Dry Eye Disease Treatment Drugs @ Drugs for Dry Eye Disease Treatment- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Eye Disease Emerging Drugs Profile

• AR-15512: Alcon
AR-15512 is an investigational eye drop currently in clinical development at Aerie as a potential treatment for the signs and symptoms of dry eye disease. It has not been approved by the US Food and Drug Administration (FDA). The active ingredient in AR-15512 is a proprietary small-molecule selective agonist of the transient receptor potential melastatin 8 (TRPM8) cold thermoreceptor, which represents a novel therapeutic target for dry eye. Currently, the drug is in Phase III stage of its development for the treatment of dry eyes disease.

• HL036: HanAll Biopharma
HL036 (tanfanercept), jointly developed by HanAll Biopharma and Daewoong Pharmaceutical, is a novel, topical biologic treatment under development to treat inflammatory eye diseases by inhibiting TNF, which is involved in ocular inflammation. The first Phase III clinical trial (VELOS-2) for dry eye disease was completed in the US. It is being developed in Phase III in China by Harbour BioMed, HanAll's out-licensing partner for the greater China region.

• OTX-DED: Ocular Therapeutix
OTX-DED, is a low dose, intracanalicular insert of dexamethasone for the treatment of patients with episodic dry eye disease. OTX-DED is designed to release dexamethasone over a period of two to three weeks for the short-term treatment of the signs and symptoms of dry eye disease. OTX-DED may offer patients the opportunity to be treated with a physician-administered, preservative-free and hands-free steroid therapy. Currently, the drug is in Phase II stage of its development for the treatment of dry eyes disease.

• SY-201: Seinda Pharmaceutical
SY-201, which is being developed by Seinda Pharmaceutical, is under developmental Phase I/II for the treatment of dry eye disease. It is administered through ophthalmic route in the form of solution.

• iVIEW 1001: IVIEW Therapeutics
IVW-1001 is a TRPM8 receptor agonist which selectively activates TRPM8 receptors and their activation has the potential to reduce discomfort. Evidence from clinical studies showed that topical TRPM8 activation reduced eye discomfort and increased tear secretion in those with DED. In January 2023, iVIEW Therapeutics announced that the company completed a successful pre-IND meeting with FDA and received the agency's full agreement on all CMC, non-clinical and clinical development plans to develop IVW-1001 for the treatment of sign and symptoms of dry eye disease (DED). The company is targeting to initiate Phase I/II clinical trials for dry eye patients in the end of 2023.

Dry Eye Disease Pipeline Therapeutics Assessment
There are approx. 45+ key Dry Eye Disease companies which are developing the Dry Eye Disease therapies. The Dry Eye Disease companies which have their drug candidates in the most advanced stage, i.e. phase III include, Alcon.

DelveInsight's Dry Eye Disease pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dry Eye Disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Dry Eye Disease Pipeline Therapies @ Dry Eye Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dry Eye Disease Pipeline Report
• Coverage- Global
• Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Dry Eye Disease Companies- Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, Seikagaku Corporation, Aramis Biosciences, Dreamhawk Vision Biotech Inc., Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa, and others.
• Dry Eye Disease Pipeline Therapies- OK-101, SHJ002/Vehicle, TL-925, SY-201 Ophthalmic Solution 2.0%, K-161, Tivanisiran sodium ophthalmic solution, Oxervate, HU007, Restasis, Moisview Eye drop, Masked Ikervis, and others.

Dive deep into rich insights for new drugs for Dry Eye Disease Treatment, Visit @ Dry Eye Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Dry Eye Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Eye Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AR-15512: Alcon
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. OTX-DED: Ocular Therapeutix
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SY-201: Seinda Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dry Eye Disease Key Companies
21. Dry Eye Disease Key Products
22. Dry Eye Disease- Unmet Needs
23. Dry Eye Disease- Market Drivers and Barriers
24. Dry Eye Disease- Future Perspectives and Conclusion
25. Dry Eye Disease Analyst Views
26. Dry Eye Disease Key Companies
27. Appendix

For further information on the Dry Eye Disease Pipeline therapeutics, reach out to Dry Eye Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.